The Playground

  • qCorticosteroids and superinfections in COVID-19 patients on invasive mechanical ventilation

    https://www.journalofinfection.com/article/S0163-4453(22)00305-X/fulltext


    Highlights

    In COVID-19 ARDS superinfections were strongly associated with the use of dexamethasone.

    Invasive fungal infections were found exclusively in dexamethasone treated patients.

    Unadjusted survival rate was decreases in patients treated with dexamethasone.

    Abstract

    Objectives

    To determine the incidence and characteristics of superinfections in mechanically ventilated COVID-19 patients, and the impact of dexamethasone as standard therapy.

    Methods

    This multicentre, observational, retrospective study included patients ≥ 18 years admitted from March 1st 2020 to January 31st 2021 with COVID-19 infection who received mechanical ventilation. Patient characteristics, clinical characteristics, therapy and survival were examined.

    Results

    155/156 patients (115 men, mean age 62 years, range 26-84 years) were included. 67 patients (43%) had 90 superinfections, pneumonia dominated (78%). Superinfections were associated with receiving dexamethasone (66% vs 32%, p<0.0001), autoimmune disease (18% vs 5.7%, p<0.016) and with longer ICU stays (26 vs 17 days, p<0,001). Invasive fungal infections were reported exclusively in dexamethasone-treated patients [8/67 (12%) vs 0/88 (0%), p<0.0001]. Unadjusted 90-day survival did not differ between patients with or without superinfections (64% vs 73%, p=0.25), but was lower in patients receiving dexamethasone versus not (58% vs 78%, p=0.007). In multiple regression analysis, superinfection was associated with dexamethasone use [OR 3.7 (1.80–7.61), p<0.001], pre-existing autoimmune disease [OR 3.82 (1.13–12.9), p=0.031] and length of ICU stay [OR 1.05 p<0.001].

    Conclusions

    In critically ill COVID-19 patients, dexamethasone as standard of care was strongly and independently associated with superinfections.

  • I wonder if the FDA, CDC, and the NIH are paying attention. Do they plan on discussing these treatments or just ignoring these nasal treatments. There are now 3 on the market around the world. Israel was the first. Not much attention being payed by the national and international media


    Anti-Covid nasal spray ready soon


    Anti-Covid nasal spray ready soon
    A locally developed nasal spray for preventing Covid-19 will be available for public use by September.
    www.bangkokpost.com


    A locally developed nasal spray for preventing Covid-19 will be available for public use by September.


    Deputy government spokeswoman Rachada Dhnadirek said Prime Minister Prayut Chan-o-cha praised the joint project responsible for developing the nasal spray.


    Experts in pharmaceutical and medical supplies from Chulalongkorn University, Silpakorn University, Health Systems Research Institute (HSRI), the Government Pharmaceutical Organisation (GPO) and Siam Bioscience worked together on the project.

  • CETI RIFEX Kit History

    Source

    padrak.com was first indexed by Google more than 10 years ago

    Patterson Power Cell Patent Information

    PATTERSON POWER CELL PATENT INFORMATION

    5 US Patents and Related Information and Data

    Patterson Power Cell Patent Information

    5 US Patents and Related Information and Data

    • A packet of information is available that includes all 5 of the latest US Patents by James A. Patterson, and additional information, that covers the development and design of the "Patterson Power Cell (TM)".
    • This packet is being offered by the INE for educational purposes only, to interested scientists and researchers.
    • The packet contains the following information and data:
    • PATENTS - The complete 5 US Patents by Patterson, as follows:
    • 4,943,355: Improved process for producing uniformly plated microspheres Filed May 16, 1989; Granted Jul. 24, 1990. 3 pp.
    • 5,036,031: Metal plated microsphere catalyst Filed Sep. 28, 1989; Granted Jul. 30, 1991 3 pp.
    • 5,318,675: Method for electrolysis of water to form metal hydride Filed Jul. 20, 1993; Granted Jun. 7, 1994 7 pp.
    • 5,372,688: System for electrolysis of liquid electrolyte Filed Dec. 2, 1993; Granted Dec. 13, 1994 8 pp.
    • 5,607,563: System for electrolysis Filed Dec. 4, 1995; Granted Mar. 4, 1997 5 pp.
    • CETI WEB PAGE INFORMATION
    • Copies of the following Clean Energy Technologies Web Site Pages:
    • CETI Main Web Page (2 pp)
    • CETI RIFEX Kit Web Page (2 pp)
    • Summarizing the CETI RIFEX (TM) Basic Research Kit: Equipment, Research License, Training, and the Research Affiliates Program.
    • CETI Technical Paper by Dr. Cravens (9 pp) Describing in detail the construction of the PPC and its internal components (May 1995).
    • PRESENTATIONS (by Hal Fox and Patrick Bailey) - "Promotion by Destruction", NEN PPC Review Article by Hal Fox (2 pp)
    • PPC Presentation Data Slides, by Patrick Bailey (14 pp)
    • TO ORDER: This packet is available for $20.00, postage paid (*), from:

    • PPC Information Packet - INE
    • P.O. Box 201 Los Altos, CA 94023-0201
    • * - For international air-mail orders, please add $4.00 additional.
  • Future historians will spend endless hours writing dissertations and scholarly tomes on all that preceded the advent of CMNS energy technologies.

    Here is a pleasant meandering article by Ruby from 2013 that touches on interesting bits of history and Jed Rothwell`s first article at Infinite Energy Magazine's second edition. It touches on Jim's beads.


    MARCH 29, 2013 BY RUBY CARAT

    "Cold Fusion-Powered Car Engineer has History of Discovery"


    Source

    coldfusionnow.org was first indexed by Google more than 10 years ago

    Cold fusion-powered car engineer has history of discovery – COLD FUSION NOW!

    From Ruby's article

    BEHIND THE SCENES AT ICCF-5 by Hal Fox

    Quote

    One of the most impressive presentations at the ICCF-5 was given by Dr. Dennis Cravens and supported by a working cold fusion cell set up in the foyer by Clean Energy Technologies, Inc. (CETI) of Dallas Texas. Attendees at the conference could take their own data, compute the results, and show that a cold fusion cell was operating at 200 to 400 percent excess thermal power. This cold fusion system utilized the patented inventions of James A. Patterson. This invention consists of small plastic beads coated with copper, nickel, and palladium. These beads provide a uniform large surface area (of either palladium or nickel) to catalyze the nuclear processes that are the heart of cold fusion phenomena. The CETI patents cover both light and heavy water electrolysis using the metal-coated microspheres.

    Writing for the second issue of Infinite Energy magazine,

    Jed Rothwell provided further details of the demo.

    Quote

    Patterson’s company, Clean Energy Technologies, Inc. (CETI), got together with Dennis Cravens and brought to the conference a demonstration cell in a flow calorimeter. It worked spectacularly well. Cravens [2] discussed it on the first day. The device output 3 to 5 times input energy, ignoring energy lost to electrolysis gases, and as much as 10 times input if you include various factors such as electrolysis gases and the heat lost from the cell container.

    As a demo, the Patterson cell output power was only a few Watts, but the durability was impressive.

    Rothwell continued:

    Quote

    The CETI demo system is fairly predictable, well controlled, and well-behaved, although it did get a bit quirky in the harsh conditions of the ICCF5 hallway. During breaks, the hotel coffee pots kept tripping the circuit breakers. This sent jolts of power through the transformer, which crashed the experiment. The CF reaction started up again every time, usually in about 10 minutes. The high precision flowmeter unfortunately did not survive the beating; the batteries and power supplies in it burned up. Fortunately, the low-precision flowmeter—a 10-ml laboratory supply graduated glass cylinder plus stopwatch—cannot be affected by power outages and excess voltage. The experiment was subjected to other abuses: the cart holding the experiment was wheeled up to a hotel room every night, carried on elevators, and pushed around. Cravens even lifted the cell from its container to show it to people while it was running! Yet in spite of this, the reaction started up in the morning after 10 or 20 minutes of electrolysis, although on the last day it took about a half hour, and the power was turned up higher than before. The fact that the cell survived this treatment at all demonstrates that this is one of the most robust and practical electrochemical CF systems yet developed.

    gbgoblenote

    Thanks Ruby

  • Why should the mafia owned media promote low cost drugs/treatments?

    Well I can't argue with that but it doesn't explain why the alphabet agencies are not discussing these treatments. I've sent numerous emails to each agency detailing these treatment and have received no response. Boosters and vaccinating 6 month olds are more a priority. A vaccine that doesn't stop infection or spread, yet ignore a nasal treatment that does prevent infection. As a taxpayer, I'm getting screwed and ignored and I'm pissed off. I don't give a rats ass who is paying them, I expect the best treatment from these agencies not a continuation of what's not working!

  • Here is a pleasant meandering article by Ruby from 2013 that touches on interesting bits of history and Jed Rothwell`s first article at Infinite Energy Magazine's second edition. It touches on Jim's beads.

    That was a public demonstration of the beads conducted by Dennis Cravens, who is a smart cookie. There was also a demonstration put on for Motorola. It was not open to the public, but they invited me and a few other people. It was less impressive. The instruments were rudimentary. The flow was clogged and the flow rate dropped midway through, but we did not know at first, because there was no on-line flowmeter. We measured by letting the flow fill a graduated cylinder. That is a good back-up method but you should not use it as the primary method. There were many problems with that demonstration. That is one of the reasons I said it was an inept marketing effort.


    Years later, Dennis told me Patterson asked him to use crude instruments, so that it would not be "too convincing" (I think he said), or too impressive. That's nuts. Always put your best foot forward. Do the best job you can.

  • Monkeypox and sexual networks.


    Our understand of sexually transmitted infections is shedding light on why monkeypox is spreading in parts of the world where it’s not often found. The virus might have made its way into the highly interconnected sexual networks of men who have sex with men (MSM). Most of the recorded cases in the current outbreak have been in MSM — although that might be partly because they choose to get health check-ups more often than other people. Researchers emphasise that it is important to avoid any stigma that could worsen discrimination. And more research is needed on how sexual encounters might play a part in transmission. But scientists are also focused on how to protect those most at risk and limit spread — for example, by offering vaccination to MSM with many sexual partners. “It’s not about who you are,” says epidemiologist and former HIV activist Gregg Gonsalves. “It’s about what you’re doing. And we’re not going to stigmatize it. But just know that you’re at greater risk if you fit this profile.”

  • Vaccination Increases Risk of COVID-19 Infection, But Infection Without Vaccination Gives Immunity: Study


    Vaccination Increases Risk of COVID-19 Infection, But Infection Without Vaccination Gives Immunity: Study
    Having two doses of a COVID-19 vaccine has been linked with negative protection against symptomatic infection with the ...
    www.theepochtimes.com


    Having two doses of a COVID-19 vaccine has been linked with negative protection against symptomatic infection with the disease, scientists say, while a previous infection without vaccination offers around 50 percent immunity, according to a study analyzing the Omicron wave in Qatar.


    The study, published in the New England Journal of Medicine on June 15, examined the Omicron wave in Qatar that occurred from around December 2021 to February 2022, comparing vaccination rates and immunity among more than 100,000 Omicron infected and non-infected individuals.


    The authors of the study found that those who had a prior infection but no vaccination had a 46.1 and 50 percent immunity against the two subvariants of the Omicron variant, even at an interval of more than 300 days since the previous infection.


    However, individuals who received two doses of the Pfizer and Moderna vaccine but had no previous infection, were found with negative immunity against both BA.1 and BA.2 Omicron subvariants, indicating an increased risk of contracting COVID-19 than an average person.


    Over six months after getting two doses of the Pfizer vaccine, immunity against any Omicron infection dropped to -3.4 percent.


    But for two doses of the Moderna vaccine, immunity against any Omicron infection dropped to -10.3 percent after more than six months since the last injection.

  • Polio virus found in London sewage samples


    Polio virus found in London sewage samples
    The last case of wild polio was contracted in 1984 and the UK has remained polio-free since 2003.
    www.axios.com


    Britain's polio-free status may be in jeopardy for the first time in nearly 20 years as several samples of the polio virus were found during recent London sewage testing, the U.K. Heath Security Agency said Wednesday.


    Why it matters: The discovery means it's likely there has been some spread of a "vaccine-derived" polio virus between close contacts in London, UKHSA said. The last case of wild polio in the U.K. was confirmed in 1984 and the country has remained polio-free since 2003.

  • If you haven't had a previous infection, Paxcrap doesn't work!!!


    Vaccinated, low-risk people won't benefit from COVID-19 pill Paxlovid: Pfizer study suggests



    Vaccinated, low-risk people won't benefit from COVID-19 pill Paxlovid: Pfizer study suggests
    Mounting evidence suggests Paxlovid may not benefit everyone equally.
    abcnews.go.com


    Pfizer's COVID-19 treatment Paxlovid has been hailed as a breakthrough in the fight against COVID-19. The pills have shown to dramatically reduce the risk of being hospitalized or dying for people who are at high-risk of COVID-19.


    But mounting evidence suggests Paxlovid may not benefit everyone equally. The company recently announced the results of a new study that found the drug did not meaningfully benefit people without underlying medical conditions or no previous infection of COVID.


    This comes weeks after the Biden administration announced plans to purchase 20 million treatment courses of the drug as it focuses on the Test-to-Treat initiative as part of the National COVID-19 Preparedness Plan.

  • Serious Adverse Events of Special Interest Following mRNA Vaccination in Randomized Trials


    Serious Adverse Events of Special Interest Following mRNA Vaccination in Randomized Trials


    Abstract

    Introduction: In 2020, prior to COVID-19 vaccine rollout, the Coalition for Epidemic Preparedness Innovations and Brighton Collaboration created a priority list, endorsed by the World Health Organization, of potential adverse events relevant to COVID-19 vaccines. We leveraged the Brighton Collaboration list to evaluate serious adverse events of special interest observed in phase III randomized trials of mRNA COVID-19 vaccines.


    Methods: Secondary analysis of serious adverse events reported in the placebo-controlled, phase III randomized clinical trials of Pfizer and Moderna mRNA COVID-19 vaccines (NCT04368728 and NCT04470427), focusing analysis on potential adverse events of special interest identified by the Brighton Collaboration.


    Results: Pfizer and Moderna mRNA COVID-19 vaccines were associated with an increased risk of serious adverse events of special interest, with an absolute risk increase of 10.1 and 15.1 per 10,000 vaccinated over placebo baselines of 17.6 and 42.2 (95% CI -0.4 to 20.6 and -3.6 to 33.8), respectively. Combined, the mRNA vaccines were associated with an absolute risk increase of serious adverse events of special interest of 12.5 per 10,000 (95% CI 2.1 to 22.9). The excess risk of serious adverse events of special interest surpassed the risk reduction for COVID-19 hospitalization relative to the placebo group in both Pfizer and Moderna trials (2.3 and 6.4 per 10,000 participants, respectively).


    Discussion: The excess risk of serious adverse events found in our study points to the need for formal harm-benefit analyses, particularly those that are stratified according to risk of serious COVID-19 outcomes such as hospitalization or death.

  • External Content youtu.be
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.